11 July 2019

Reminder: EUnetHTA Joint Assessment Coming to a Close

Just as a reminder from one of our previous posts, the opportunity for open patient input in one of EUnetHTA’s joint assessment on patients using the new drug brolucizumab for treatment of neovascular age-related macular degeneration, or wet AMD, is coming to a close. The chance to contribute to this opportunity closes on July 15th, 13:00PM CEST. Follow the link below to contribute!



Join Our Mailing List

To keep up to date with our news and activities, please complete this simple form

Retina International
Ausstellungsstr. 36
8005 Zurich

Follow Us

This site has been supported through an unrestricted educational grant from Novartis

Font Resize
High Contrast